Wesbanco Bank Inc. Has $947,000 Stock Position in LeMaitre Vascular, Inc. $LMAT

Key Points

• Wesbanco Bank Inc. increased its stake in LeMaitre Vascular by 103.6%, owning approximately 11,400 shares valued at $947,000.
• LeMaitre Vascular's stock received upgraded ratings from analysts, with a consensus price target of $97.60 and a mix of Buy and Hold ratings.
• Insider selling was notable, with directors disposing of a total of 120,815 shares worth over $11 million in the last quarter.

Wesbanco Bank Inc. grew its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 103.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,400 shares of the medical instruments supplier's stock after purchasing an additional 5,800 shares during the period. Wesbanco Bank Inc. owned approximately 0.05% of LeMaitre Vascular worth $947,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the stock. Strs Ohio acquired a new position in shares of LeMaitre Vascular in the 1st quarter worth approximately $168,000. Geneos Wealth Management Inc. raised its holdings in shares of LeMaitre Vascular by 250.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier's stock worth $47,000 after buying an additional 398 shares in the last quarter. Intech Investment Management LLC raised its holdings in shares of LeMaitre Vascular by 116.6% in the 1st quarter. Intech Investment Management LLC now owns 20,967 shares of the medical instruments supplier's stock worth $1,759,000 after buying an additional 11,288 shares in the last quarter. Jane Street Group LLC raised its holdings in shares of LeMaitre Vascular by 738.7% in the 1st quarter. Jane Street Group LLC now owns 20,096 shares of the medical instruments supplier's stock worth $1,686,000 after buying an additional 17,700 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of LeMaitre Vascular by 5.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 37,709 shares of the medical instruments supplier's stock worth $3,164,000 after buying an additional 1,972 shares in the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on LMAT shares. Cantor Fitzgerald increased their target price on LeMaitre Vascular from $92.00 to $95.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Barrington Research raised LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 target price on the stock in a report on Wednesday, August 6th. Two investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $97.60.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, Director Bridget A. Ross sold 2,500 shares of LeMaitre Vascular stock in a transaction on Friday, August 8th. The shares were sold at an average price of $94.00, for a total transaction of $235,000.00. Following the completion of the sale, the director owned 2,916 shares of the company's stock, valued at approximately $274,104. The trade was a 46.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David B. Roberts sold 10,815 shares of LeMaitre Vascular stock in a transaction on Monday, August 11th. The stock was sold at an average price of $92.39, for a total transaction of $999,197.85. Following the sale, the director directly owned 17,976 shares of the company's stock, valued at $1,660,802.64. This represents a 37.56% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 120,815 shares of company stock worth $11,280,206 over the last quarter. 9.50% of the stock is currently owned by insiders.

LeMaitre Vascular Stock Performance

LMAT stock opened at $92.37 on Tuesday. The company has a debt-to-equity ratio of 0.46, a current ratio of 13.96 and a quick ratio of 11.74. The company has a 50 day moving average price of $89.88 and a 200 day moving average price of $85.85. LeMaitre Vascular, Inc. has a fifty-two week low of $71.42 and a fifty-two week high of $109.58. The stock has a market capitalization of $2.09 billion, a PE ratio of 44.84, a price-to-earnings-growth ratio of 2.37 and a beta of 0.79.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.03. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The firm had revenue of $63.15 million during the quarter, compared to analysts' expectations of $62.48 million. During the same quarter in the previous year, the company posted $0.52 EPS. LeMaitre Vascular's revenue was up 15.0% on a year-over-year basis. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. Analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 4th. Shareholders of record on Thursday, August 21st were issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend was Thursday, August 21st. LeMaitre Vascular's payout ratio is currently 38.83%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.